Barclays PLC Xencor Inc Transaction History

Barclays PLC

$353 Billion
Q1 2025

A detailed history of Barclays PLC transactions in Xencor Inc stock. As of the latest transaction made, Barclays PLC holds 178,260 shares of XNCR stock, worth $1.38 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

178,260

Previous 330,745 46.1%

Holding current value

$1.38 Million

Previous $7.6 Million 75.04%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$10.64 - $24.13 $1.62 Million - $3.68 Million	-152,485 Reduced 46.1%	178,260 $1.9 Million
Q4 2024 Feb 13, 2025	BUY	$19.43 - $26.84 $3.4 Million - $4.7 Million	175,177 Added 112.6%	330,745 $7.6 Million
Q3 2024 Nov 15, 2024	BUY	$15.7 - $21.65 $1.23 Million - $1.69 Million	78,066 Added 100.73%	155,568 $3.13 Million
Q2 2024 Aug 14, 2024	SELL	$18.21 - $24.5 $376,273 - $506,243	-20,663 Reduced 21.05%	77,502 $1.47 Million
Q1 2024 May 15, 2024	SELL	$18.65 - $26.52 $3.18 Million - $4.52 Million	-170,334 Reduced 63.44%	98,165 $2.17 Million
Q4 2023 Feb 15, 2024	BUY	$16.53 - $21.42 $2.7 Million - $3.5 Million	163,582 Added 155.92%	268,499 $5.7 Million
Q3 2023 Nov 07, 2023	BUY	$20.08 - $25.39 $351,962 - $445,035	17,528 Added 20.06%	104,917 $2.12 Million
Q2 2023 Aug 03, 2023	BUY	$24.77 - $29.9 $361,419 - $436,270	14,591 Added 20.04%	87,389 $2.18 Million
Q1 2023 May 04, 2023	SELL	$25.95 - $36.95 $468,631 - $667,280	-18,059 Reduced 19.88%	72,798 $2.03 Million
Q4 2022 Feb 13, 2023	BUY	$24.79 - $30.86 $123,379 - $153,590	4,977 Added 5.8%	90,857 $2.37 Million
Q3 2022 Nov 03, 2022	BUY	$24.62 - $32.44 $1.66 Million - $2.19 Million	67,447 Added 365.9%	85,880 $2.23 Million
Q2 2022 Aug 12, 2022	SELL	$19.74 - $29.01 $574,216 - $843,871	-29,089 Reduced 61.21%	18,433 $505,000
Q1 2022 May 16, 2022	SELL	$26.68 - $41.63 $706,593 - $1.1 Million	-26,484 Reduced 35.79%	47,522 $1.27 Million
Q4 2021 Feb 14, 2022	BUY	$33.67 - $43.44 $745,824 - $962,239	22,151 Added 42.72%	74,006 $2.97 Million
Q3 2021 Nov 09, 2021	BUY	$30.65 - $35.68 $295,220 - $343,669	9,632 Added 22.81%	51,855 $1.69 Million
Q2 2021 Aug 13, 2021	SELL	$34.33 - $44.68 $1.13 Million - $1.47 Million	-32,911 Reduced 43.8%	42,223 $1.46 Million
Q1 2021 May 13, 2021	BUY	$40.81 - $53.88 $290,648 - $383,733	7,122 Added 10.47%	75,134 $3.24 Million
Q4 2020 Feb 11, 2021	SELL	$36.63 - $47.63 $2.29 Million - $2.98 Million	-62,471 Reduced 47.88%	68,012 $2.97 Million
Q3 2020 Nov 12, 2020	BUY	$30.09 - $43.02 $1.91 Million - $2.73 Million	63,346 Added 94.35%	130,483 $5.06 Million
Q2 2020 Aug 12, 2020	SELL	$27.76 - $33.42 $144,823 - $174,352	-5,217 Reduced 7.21%	67,137 $2.18 Million
Q1 2020 May 13, 2020	SELL	$20.69 - $37.79 $323,136 - $590,204	-15,618 Reduced 17.75%	72,354 $2.16 Million
Q4 2019 Feb 10, 2020	BUY	$32.75 - $41.43 $1.11 Million - $1.4 Million	33,829 Added 62.48%	87,972 $3.03 Million
Q3 2019 Nov 14, 2019	BUY	$33.73 - $46.27 $790,597 - $1.08 Million	23,439 Added 76.34%	54,143 $1.83 Million
Q2 2019 Aug 14, 2019	BUY	$29.6 - $40.93 $518,000 - $716,275	17,500 Added 132.54%	30,704 $1.26 Million
Q1 2019 May 15, 2019	BUY	$27.85 - $38.09 $367,731 - $502,940	13,204 New	13,204 $410,000
Q4 2018 Feb 14, 2019	SELL	$32.39 - $42.05 $1.06 Million - $1.38 Million	-32,770 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$35.69 - $47.65 $702,593 - $938,037	19,686 Added 150.46%	32,770 $1.28 Million
Q2 2018 Aug 14, 2018	BUY	$28.41 - $42.41 $117,162 - $174,898	4,124 Added 46.03%	13,084 $484,000
Q1 2018 May 15, 2018	BUY	$21.18 - $33.78 $53,331 - $85,058	2,518 Added 39.09%	8,960 $269,000
Q4 2017 Feb 14, 2018	BUY	$19.29 - $24.83 $45,755 - $58,896	2,372 Added 58.28%	6,442 $141,000
Q3 2017 Nov 14, 2017	BUY	$19.61 - $23.35 $79,812 - $95,034	4,070	4,070 $94,000

Others Institutions Holding XNCR

# of Institutions

211

Shares Held

78.4M

Call Options Held

3.4K

Put Options Held

1.9K

View Full List

About Xencor Inc

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $463M
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

More about XNCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account